The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO ... approval by the Chinese National Medical Products Administration for reducing GGP occurrence ...

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

"With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams ...

For Boehringer, the deal adds to a broad pipeline in schizophrenia that spans both pharmacological and digital therapeutic (DTx) products. Leading the charge for new drug therapies is iclepertin ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals ... Hilberdink successfully launched multiple blockbuster products in the fields of obesity and diabetes.

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...

parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...